Trans women develop breasts primarily through hormone therapy, which triggers the same biological process that drives breast growth during puberty in cisgender women. Estrogen stimulates the growth of breast ducts and surrounding tissue, while medications that suppress testosterone allow this process to proceed. For many trans women, hormone therapy alone produces modest breast growth, and some pursue surgical augmentation for additional size.
How Hormones Trigger Breast Growth
Breast development in trans women relies on two simultaneous hormonal shifts: raising estrogen levels and lowering testosterone. Estrogen on its own can reduce testosterone into the low-normal male range (roughly 200 to 300 ng/dL), but that’s still well above the typical female range of under 75 ng/dL. Most people need an additional anti-androgen medication to bring testosterone low enough for estrogen to do its work effectively.
The two most common anti-androgens are spironolactone and cyproterone acetate. Spironolactone, widely prescribed in the U.S., brings average testosterone levels down to about 87 ng/dL when combined with estrogen. Cyproterone, more common outside the U.S., is more potent and can suppress testosterone to under 30 ng/dL when paired with estrogen. Once testosterone drops into the female range, estrogen can drive breast tissue formation, fat redistribution to the hips and chest, and softer skin.
What the Growth Timeline Looks Like
Breast buds typically become noticeable under the nipple within 2 to 3 months of starting combined estrogen and anti-androgen therapy. From there, the bulk of growth happens in the first 6 months. Development continues at a slower pace and generally plateaus within 2 to 3 years.
A study tracking 224 trans women during their first year of estrogen therapy found that most measurable growth occurred in the first 6 months and nearly stopped in the second half of the year. This mirrors the pattern of puberty in cisgender girls, where breast growth happens in bursts before leveling off, though trans women on average reach a smaller final size.
How Much Growth to Realistically Expect
This is where expectations and reality often diverge. After 3 years of hormone therapy, 73% of trans women in one study had a cup size smaller than A. The median breast volume measured was 115 mL, which corresponds to less than an A cup. In another cohort, fewer than half reached the smallest standard cup size (AAA), and only 3.6% achieved larger than an A cup.
Full adult breast development, classified as Tanner stage V in medical terms (the final stage of breast maturity), is unlikely even with well-managed hormone therapy. Most trans women reach an intermediate stage of development. Starting hormones at too high a dose early on can actually backfire: aggressive regimens may cause rapid initial growth but risk halting the branching process of breast ducts prematurely, locking development at an earlier stage. Gradual dose increases are the standard approach for this reason.
Factors That Influence Final Size
You might expect that age, body weight, or estrogen dose would predict how much breast growth someone gets. A prospective study of trans women in their first year of hormone therapy found that none of these factors made a significant difference. Age at the start of treatment, weight changes during treatment, BMI, smoking status, estrogen blood levels, and the method of taking estrogen (pills, patches, or injections) all failed to predict final breast size.
Genetics likely play the largest role, just as they do for cisgender women. If close female relatives have smaller breasts, a trans woman on hormone therapy is more likely to have modest results as well. The variability between individuals is wide, and there’s currently no reliable way to predict where someone will land.
The Question of Progesterone
Many trans women add progesterone to their hormone regimen, hoping it will push breast development further. In a U.S. survey of trans women and gender-diverse adults, 85% of those who started progesterone cited breast development as the reason, and about 80% felt it improved their results. However, there isn’t strong objective evidence yet that progesterone reliably increases breast size or advances development to a more mature stage. It remains one of the more debated topics in transgender hormone therapy, with many people reporting subjective improvements in breast fullness and shape.
Breast Augmentation Surgery
Because hormone therapy alone produces results that many trans women find insufficient, breast augmentation is one of the most commonly sought gender-affirming surgeries. Surgeons generally recommend at least 1 to 2 years of hormone therapy before considering implants, both to allow natural growth to plateau and to let chest tissue soften enough for a good surgical result.
The surgical approach differs from typical breast augmentation in a few important ways. Trans women generally have wider chests with nipples positioned more toward the sides. Surgeons typically place implants beneath the chest muscle rather than above it, since there’s less overlying breast tissue to provide natural coverage. The implant can be centered behind the nipple, which limits cleavage, or shifted slightly inward for a more traditionally feminine look, though this leaves the nipples sitting more laterally on the breast mound. Fat grafting is sometimes used to smooth the inner breast area, but achieving deep cleavage remains a challenge given chest anatomy.
Implant size is chosen based on chest width, body proportions, and soft tissue thickness. Interestingly, longer time on hormones before surgery has been associated with higher rates of dissatisfaction with surgical results, possibly because extended hormone use sets expectations that surgery doesn’t fully meet, or because the tissue characteristics change over time. Higher BMI and longer preoperative hormone duration were also linked to higher complication rates.
Breast Health and Screening
Trans women on long-term hormone therapy do develop real breast tissue, which means breast cancer becomes a relevant, if small, risk. Current guidelines recommend that trans women with intact breast tissue who are on hormone therapy consider mammograms or breast MRI starting at age 40, or 5 to 10 years after beginning hormones, whichever comes first. Screening decisions factor in age at transition, how long someone has been on hormones, family history, and how much breast tissue has developed.